Select Language
IL-2 R beta & IL-2 R alpha & IL-2 R gamma
IL-2 R beta & IL-2 R alpha & IL-2 R gamma Overview
| English Name | Interleukin-2 | Approved Drugs | 2 |
| Drugs in Clinical Trials | 41 | Target Synonym | T-cell growth factor，IL2，Interleukin 2，T Cell Growth Factor，Aldesleukin，IL-2，TCGF，Involved In Regulation Of T-Cell Clonal Expansion，Interleukin-2，Lymphokine |
| Highest Development Stage | Approved | ||
| English Name | Interleukin-2 |
| Target Synonym | T-cell growth factor，IL2，Interleukin 2，T Cell Growth Factor，Aldesleukin，IL-2，TCGF，Involved In Regulation Of T-Cell Clonal Expansion，Interleukin-2，Lymphokine |
| Approved Drugs | 2 |
| Drugs in Clinical Trials | 41 |
| Highest Development Stage | Approved |
IL-2 R beta & IL-2 R alpha & IL-2 R gamma Product List
- Product Category
Protein (9)
- Product Status
Launched (9)
- Species
Human (4)Mouse (1)Cynomolgus (3)Rat (1)
- Tag
Fc Tag (2)Fc Tag & Avi Tag (3)His Tag & Strep Tag (2)- (2)
- Conjugate
Unconjugated (5)Biotin-labeled (4)
Total: 9
- 1
IL-2 R beta & IL-2 R alpha & IL-2 R gamma Background
Both Interleukin-2 receptor subunit beta and Interleukin-2 receptor subunit gamma are receptor for interleukin-2. Common subunit for the receptors for a variety of interleukins. Interacts with SHB upon interleukin stimulation. Probably in association with IL15RA, involved in the stimulation of neutrophil phagocytosis by IL15. This beta subunit is involved in receptor mediated endocytosis and transduces the mitogenic signals of IL2. IL2R exists in 3 different forms: a high affinity dimer, an intermediate affinity monomer (beta subunit), and a low affinity monomer (alpha subunit). The high and intermediate affinity forms also associate with a gamma subunit.
IL-2 R beta & IL-2 R alpha & IL-2 R gamma Synonyms
IL-2 R beta & IL-2 R alpha & IL-2 R gamma
Clinical Drug Information
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Darleukin/fibromun | L19-IL-2/ L19-TNF-α | Phase 3 Clinical | Philogen Spa | Carcinoma, Merkel Cell; Carcinoma, Basal Cell; Carcinoma, Skin Appendage; Keratoacanthoma; Basal Cell Nevus Syndrome; Carcinoma, Squamous Cell; Lymphoma, T-Cell, Cutaneous; Melanoma; Sarcoma, Kaposi | Details |
| Bifikafusp alfa | L19-IL-2 | Phase 3 Clinical | Philogen Spa | Solid tumours; Adenomatous Polyposis Coli; Pancreatic Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| EQ-101 | EQ101; EQ-101; BNZ132-1-40; BNZ-1; BNZ132-1; BNZ-01 | Phase 2 Clinical | Bioniz Therapeutics Inc | Alopecia; Alopecia Areata; Lymphoma, T-Cell, Cutaneous; Leukemia, Large Granular Lymphocytic | Details |
| umitrelimorgene autodencel | ITI-1000 | Phase 2 Clinical | Immunomic Therapeutics Inc | Glioblastoma | Details |
| S-95007 | S-95007 | Phase 2 Clinical | Laboratoires Servier | Immune System Diseases; Inflammation | Details |
| AU-007 | BDG-8; BD-8; AU-007 | Phase 2 Clinical | Biolojic Design Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
| XTX-202 | XTX-202 | Phase 2 Clinical | Xilio Development Inc, Xilio Therapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Melanoma | Details |
| EGL-001 | EGL-001 | Phase 2 Clinical | Egle Therapeutics | Solid tumours; Neoplasms | Details |
| STI-7349 | STI-7349 | Phase 2 Clinical | The Fourth Affiliated Hospital, Zhejiang University School Of Medcine | Solid tumours | Details |
| LAT-010 | LAT010; LAT-010 | Phase 2 Clinical | Latticon Antibody Therapeutics Inc | Solid tumours; Neoplasm Metastasis | Details |
| COYA-302 | COYA302; COYA 302; COYA-302 | Phase 2 Clinical | Coya Therapeutics Inc | Parkinson Disease; Frontotemporal Dementia; Amyotrophic Lateral Sclerosis | Details |
| KB-707 | KB707; KB-707 | Phase 2 Clinical | Krystal Biotech Inc | Solid tumours; Skin Melanoma; Neoplasms; Lung Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| REGN-10597 | REGN-10597 | Phase 2 Clinical | Regeneron Pharmaceuticals Inc | Solid tumours; Carcinoma, Renal Cell; Neoplasms; Melanoma | Details |
| IBI-363 | IBI-363 | Phase 2 Clinical | Innovent Biologics(Suzhou) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Stomach Neoplasms; Mucosal Melanoma; Neoplasms; Colorectal Neoplasms; Lymphoma; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| Saltikva | MDB401B | Phase 2 Clinical | Salspera LLC, Sunshine Lake Pharma | Pancreatic Neoplasms | Details |
| LMBP2-specific TCR-T cell therapy (TCRCure Biopharma) | Phase 2 Clinical | Tcrcure Biopharma Ltd | Nasopharyngeal Carcinoma | Details | |
| Interleukin-2 gene therapy (St Jude Children's Research Hospital) | Phase 1 Clinical | St. Jude Children'S Research Hospital, National Cancer Institute | Neuroblastoma | Details | |
| T20K | T-20K | Phase 1 Clinical | Cyxone | Multiple Sclerosis | Details |
| ODC-IL2 | ODC-IL-2; ODC-IL2; ODC-1L2 | Phase 1 Clinical | Trutino Biosciences Inc | Solid tumours; Neoplasms | Details |
| SIM-0278 | ALM-223; SIM0278 | Phase 1 Clinical | Simcere Pharmaceutical Group Ltd | Autoimmune Diseases; Lupus Erythematosus, Systemic; Dermatitis, Atopic | Details |
| Mableukin 2PD1 (Anwita Biosciences) | AWT020; AWT-020 | Phase 1 Clinical | Anwita Biosciences Inc | Solid tumours; Carcinoma, Renal Cell; Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma; Autoimmune Diseases of the Nervous System | Details |
| AB-248 | AB-248 | Phase 1 Clinical | Asher Biotherapeutics Inc | Solid tumours; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| ASP-1012 | VET2-L2; ASP-1012; ASP1012 | Phase 1 Clinical | KaliVir Immunotherapeutics Inc | Solid tumours | Details |
| STK-012 | STK-012 | Phase 1 Clinical | Synthekine Inc | Solid tumours; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Esophageal Neoplasms; Stomach Neoplasms; Mismatch Repair Deficient Cancer; Carcinoma, Transitional Cell; Microsatellite instability-high cancer; Uterine Cervical Neoplasms; Carcinoma, Non-Small-Cell Lung; Melanoma | Details |
| TEV-278 | TEV-278; TEV-‘278 | Phase 1 Clinical | Teva Pharmaceutical Industries Ltd | Neoplasms | Details |
| HM-16390 | HM-16390; HM16390 | Phase 1 Clinical | Hanmi Pharmaceutical Co Ltd | Solid tumours | Details |
| IL2 CD25 fusion protein (Bristol-Myers Squibb) | Phase 1 Clinical | University Of Miami | Autoimmune Diseases | Details | |
| KYS-202003-A | KYS-202003-A; KYS202003A | Phase 1 Clinical | Jiangsu Kanion Pharmaceutical Co Ltd | Solid tumours | Details |
| M5A-IL2 Immunocytokine | M5A-ICK | Phase 1 Clinical | National Cancer Institute, City Of Hope National Medical Center | Breast Neoplasms; Colorectal Neoplasms | Details |
| DF-6215 | DF6215; DF-6215 | Phase 1 Clinical | Dragonfly Therapeutics Llc | Solid tumours | Details |
| Dodekin | Phase 1 Clinical | Philogen Spa | Solid tumours | Details | |
| AttIL2-T cell therapy | Phase 1 Clinical | The University Of Texas MD Anderson Cancer Center | Soft Tissue Neoplasms; Osteosarcoma; Sarcoma | Details | |
| Autologous tumor-infiltrating lymphocyte cells therapy (Hervor Therapeutics) | HV-101; HV101 | Phase 1 Clinical | Hervor Therapeutics, Tcrcure Biopharma Ltd, Hangzhou Houwu Biomedical Technology Co Ltd | Solid tumours | Details |
| KY-0118 | KY-0118; KY0118 | Phase 1 Clinical | Novatim Immune Therapeutics (Zhejiang) Co Ltd | Solid tumours; Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |
| VIS171 | VIS-171; VIS171 | Phase 1 Clinical | Visterra Inc | Alopecia Areata; Autoimmune Diseases; Glomerulosclerosis, Focal Segmental; Lupus Erythematosus, Systemic | Details |
| MK-1484 | MK-1484; SP-482 | Phase 1 Clinical | Merck & Co Inc, Sutro Biopharma Inc | Solid tumours | Details |
| CUG-252 | CUG-252 | Phase 1 Clinical | Cugene Inc | Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| SAR-444336 | SAR-444336 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| RS-2102 | RS2102 | Phase 1 Clinical | Reistone Biopharma Co Ltd | Dermatitis, Atopic | Details |
| BNT-153 | BNT-153 | Phase 1 Clinical | Biontech Se | Solid tumours | Details |
| Igrelimogene litadenorepvec | PM-1016; PM1016; TILT-123 | Phase 1 Clinical | Tilt Biotherapeutics Ltd | Ovarian Neoplasms; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Peritoneal Neoplasms; Fallopian Tube Neoplasms; Lung Neoplasms; Carcinoma, Hepatocellular; Melanoma | Details |
Marketed Drug Information
| English Name | Research Code | Highest Development Stage | Company | Earliest Brand Name | Earliest Approval Country | Earliest Indication | Earliest Approval Company | Earliest Approval Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Propagermanium | SK-818; SK-818C | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Serocion | Japan | Hepatitis B | Sanwa Kagaku Kenkyusho Co Ltd | 1994-01-01 | Hepatitis B | Details |
| Thalidomide | NSC-66847; NSC-527179; K-17; FPF-300; FPF300 | Approved | Celgene Corp | Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled | Mainland China | Leprosy, Lepromatous; Multiple Myeloma | Changzhou Pharmaceutical Factory | 1982-01-01 | Xerostomia; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Prostatitis; Primary Myelofibrosis; Osteosarcoma; Cholangitis, Sclerosing; Lymphoma, Mantle-Cell; Lymphoma, Follicular; Adenocarcinoma, Clear Cell; Carcinoma, Adenosquamous; Epilepsy; Erythema Nodosum; Sarcoma; HIV Wasting Syndrome; Pancreatitis, Chronic; Sarcoma, Ewing; Arachnoiditis; Gastrointestinal Hemorrhage; Retinoblastoma; Prostatic Neoplasms; Endometriosis; Lung Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Vascular Malformations; Myelodysplastic-Myeloproliferative Diseases; Mycobacterium avium-intracellulare Infection; Amyotrophic Lateral Sclerosis; Carcinoma, Hepatocellular; Burning Mouth Syndrome; Stomatitis; Neoplasm Metastasis; Appendiceal Neoplasms; Tuberculosis; Lymphoma, Non-Hodgkin; Angiodysplasia; Pelvic Pain; Glioma; Waldenstrom Macroglobulinemia; Leprosy, Lepromatous; Endometrial Neoplasms; Uterine Neoplasms; Anemia, Sideroblastic; Ovarian Neoplasms; Gastric Antral Vascular Ectasia; Lupus Erythematosus, Discoid; Carc | Details |
- Overview
- Product List
- Marketed Drug Information
- Clinical Drug Information
Share to:
Online Message
[North America]: 1 Innovation Way, Newark, DE 19711, USA [Switzerland]: Switzerland Innovation Park Basel Area, Novartis Campus, Lichtstrasse 35, 4056 Basel
Email：order@acrobiosystems.com
Copyright © 2025 ACROBiosystems. All Rights Reserved
Contact Us
[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland